[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582571":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":58,"collaborators":25,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":25,"enrollmentInfo":69,"targetDuration":25,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":79,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Centre Hospitalier Universitaire, Amiens","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"experimental group","EXPERIMENTAL","Administration in the interventional arm of long-acting inhaled ß-2 mimetics:\n\nFORMOTEROL FUMARATE 12 µg pwd inhalation capsule (FORMOTEROL VIATRIS®), taken twice a day intraoperatively from Day-2 to Day 7.",[13],"Drug: Formoterol Fumarate 12 mcg (Foradil Aerolizer)",{"label":15,"type":16,"description":17,"interventionNames":18},"control group","SHAM_COMPARATOR","The trial was conducted as an open-label study for the control group.",[19],"Other: Usual treatment",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","Formoterol Fumarate 12 mcg (Foradil Aerolizer)",[9],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Usual treatment","usual treatment",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"THOMAS LEFEBVRE, MD","CONTACT","33 + 322087889","Lefebvre.Thomas@chu-amiens.fr",[37],{"facility":38,"status":39,"city":40,"state":25,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"CHRU Amiens","RECRUITING","Amiens","80054","France","FR",{"type":45,"coordinates":46},"Point",[47,48],2.3,49.9,{"lat":48,"lon":47},[51,53,56],{"name":32,"role":33,"phone":52,"phoneExt":25,"email":35},"33+322087889",{"name":54,"role":55,"phone":25,"phoneExt":25,"email":25},"Osama ABOU ARAB, Pr","SUB_INVESTIGATOR",{"name":57,"role":55,"phone":25,"phoneExt":25,"email":25},"Florence DE DOMINICIS, MD",{"type":59,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100582571","perioperative-inhaled-therapy-in-carcinological-thoracic-surgery-in-patients-at-high-risk-of-postoperative-pulmonary-complications-100582571",false,"NCT06865040","Perioperative Inhaled Therapy in Carcinological Thoracic Surgery in Patients at High Risk of Postoperative Pulmonary Complications","TICTAC","Inclusion Criteria:\n\n* Adult (\\>18 years)\n* Lung cancer eligible for surgical management by lung resection (non-small cell lung carcinoma = NSCLC) by any route\n* Naïve to long-term inhaled bronchodilator therapy\n* High risk of post-operative pulmonary complications (Pre-operative FEV1 \\\u003C 80%)\n\nExclusion Criteria:\n\n* Patient refusal\n* Pregnancy\n* Emergency surgery\n* Patient with a physiological status of WHO IV or ASA ≥ IV\n* Asthma\n* Patients treated with long-acting bronchodilators\n* Severe heart failure (NYHA IV), unstable ischaemic heart disease (angina or recent infarction \\\u003C 3 months), obstructive hypertrophic cardiomyopathy, subvalvular aortic stenosis, severe uncontrolled hypertension Recent stroke \\\u003C 3 months\n* High-grade unresponsive conductive disorders or unstable arrhythmia\n* Thyrotoxicosis, pheochromocytoma\n* Unbalanced diabetes\n* Hypersensitivity to ß-2 mimetics or lactose\n* Current participation in a trial of another drug therapy","ALL","18 Years",{"count":70,"type":71},266,"ESTIMATED","INTERVENTIONAL",[74],"NA","The objective of the study is to evaluate, in a clinical trial, the efficacy of peri operative administration of long-acting inhaled ß-2 mimetics on the occurrence of postoperative pulmonary complications",[77,78],"Thoracic Surgery","Postoperative Pulmonary Complications (PPCs)",[80,81,82,83,84],"Thoracic surgery","postoperative pulmonary complications","Inhaled therapy","bronchodilators","B2 mimetics","2026-01-15",{"date":87,"type":88},"2026-01-16","ACTUAL",{"date":90,"type":88},"2025-07-31",{"date":92,"type":71},"2028-09",{"name":5,"class":6},1]